China Isotope & Radiation Corp
HKEX:1763
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
Country | Company | Market Cap | ROE | ||
---|---|---|---|---|---|
CN |
C
|
China Isotope & Radiation Corp
HKEX:1763
|
4.1B HKD |
8%
|
|
CH |
![]() |
Alcon AG
SIX:ALC
|
35B CHF |
5%
|
|
JP |
![]() |
Hoya Corp
TSE:7741
|
5.9T JPY |
21%
|
|
DK |
![]() |
Coloplast A/S
CSE:COLO B
|
143.2B DKK |
27%
|
|
US |
![]() |
Align Technology Inc
NASDAQ:ALGN
|
13.2B USD |
11%
|
|
UK |
![]() |
ConvaTec Group PLC
LSE:CTEC
|
5.9B GBP |
11%
|
|
CN |
![]() |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
47.1B CNY |
17%
|
|
CH |
![]() |
Ypsomed Holding AG
SIX:YPSN
|
5.5B CHF |
13%
|
|
US |
![]() |
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.6B USD |
9%
|
|
KR |
H
|
HLB Inc
KOSDAQ:028300
|
7.2T KRW |
-34%
|
|
US |
![]() |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.2B USD |
24%
|
China Isotope & Radiation Corp
Glance View
China Isotope & Radiation Corp. engages in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-07-06. The firm also provides radiation sterilization services. The firm is also involved in the design, manufacture and installation of Gama ray irradiation devices. The firm opeartes its businesse mainly through four segments, including the Pharmaceuticals segment, the Radiological Products segment, the Irradiation segment and the Independent Medical Laboratory Services and Others segment, with the Pharmaceuticals segment as the core segment. The Pharmaceuticals segment is engaged in the development, manufacture and sale of radiopharmaceuticals, the Kit for Urea Breath Test and testing instruments, as well as in vitro immunodiagnostic reagents and boxes for imaging diagnosis and treatment.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on China Isotope & Radiation Corp's most recent financial statements, the company has ROE of 8.4%.